| COVID-19 |
1 |
1 |
| Post-Acute Sequelae of SARS-CoV-2 Infection |
0 |
0.91 |
| Biologic Therapy |
0 |
0.25 |
| Monoclonal Antibody |
0 |
0.24 |
| Patient Safety |
0 |
0.2 |
| Adverse Effects |
0 |
0.17 |
| California |
0 |
0.14 |
| Selective Serotonin-Reuptake Inhibitors |
0 |
0.13 |
| Healthcare and Medical Technology |
0 |
0.11 |
| Antiviral Agents |
0 |
0.1 |
| Blood |
0 |
0.1 |
| Clinical Research |
0 |
0.1 |
| Rheumatoid Arthritis |
0 |
0.1 |
| Arthritis |
0 |
0.07 |
| Diarrhea |
0 |
0.06 |
| Otolaryngology |
0 |
0.06 |
| Pain Management |
0 |
0.06 |